NCT04126473 - A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

April 6, 2022

Study Completion Date

April 6, 2022

Conditions

Cystic Fibrosis

Interventions

DRUG

ELX-02

ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).

DRUG

Ivacaftor

CFTR potentiator

Trial Locations (9)

2050

The Royal Prince Alfred Hospital, Camperdown

45239

Universitätsmedizin Essen Ruhrlandklinik, Essen

Unknown

The Royal Adelaide Hospital, Adelaide

The Alfred Hospital, Melbourne

Universitätsklinikum Frankfurt, Frankfurt

Carmel Medical Center, Haifa

Hadassah Medical Center, Jerusalem

Schneider Children's Medical Center, Petach Tikvah

Safra Children's Hospital - Chaim Sheba Medical Center, Ramat Gan